相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
T S K Mok et al.
ANNALS OF ONCOLOGY (2019)
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
Yen-Ting Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Yuichiro Ohe et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Pedro N. Aguiar et al.
JAMA ONCOLOGY (2018)
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
Po-Lan Su et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
Sheng-Kai Liang et al.
ONCOTARGET (2017)
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
J. J. Yang et al.
BRITISH JOURNAL OF CANCER (2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
J. C. -H. Yang et al.
ANNALS OF ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
Feng-Che Kuan et al.
BRITISH JOURNAL OF CANCER (2015)
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Verification of Wild-Type EGFR Status in Non-Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases
Yi-Lin Chen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer:: a study of absolute and relative survival over 15 years
R Båtevik et al.
LUNG CANCER (2005)
Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma
A Bajard et al.
LUNG CANCER (2004)
分享论文
